Hever Group Survey on Covid-19 Pandemic
Pharmaceutical Companies have a long tradition of collaborating in pre-competitive partnerships to share data and knowledge. The Hever Group that comprises the most senior R&D Directors from the “Top 20” (by R&D spend) Pharmaceutical Companies was established 25 years ago by Prof Trevor Jones (formerly R&D DIrector at Wellcome) and meets annually together with the Directors of US FDA, NIH and the EU EMA .
One of its main aims is to reduce attrition in drug discovery and development and reduce time to market so to optimise patient access to new medicines and the ROI of R&D investment.
In recent years, following the SARS and Ebola outbreaks, the Group has discussed pandemic preparedness and its members have been closely associated with the recent C.E.P.I. initiative.
The Covid-19 pandemic demands that we collaborate to find drugs that could be repurposed and to find new drugs and vaccines against the virus.
As a matter of urgency, the Group commissioned a survey of what work is in progress . Given the rapidly changing scenarios, this will be updated as appropriate.
Click here to view report on Covid-19 from London Strategy.
Click here to view the Hever Group Survey on Covid-19 Pandemic.
The Academy of Medical Sciences-COVID-19 preclinical drug development database
This database aims to enhance the UK’s research response to COVID-19 by collating and sharing ongoing preclinical drug discovery and development research.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.